BMS' Sprycel loses out to Novartis' discounted Tasigna in England
This article was originally published in Scrip
BMS's Sprycel (dasatinib) appears to have lost out to Novartis' Tasigna (nilotinib) as an NHS funded treatment option for chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) because of cost. NICE, the health technology appraisal body for England and Wales, said a preliminary yes to the Glivec follow-on after Novartis offered a discount. NICE has again endorsed the use of Glivec 400mg, but Bristol-Myers Squibb failed to convince the institute that its competitor drug, Sprycel (dasatinib), would be a cost-effective option.